Comparison of the subjective well-being and tolerability of quetiapine XR to risperidone - RECOVER
Study identifier:D1443L00039
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A One-Year Randomized, Prospective, Parallel, Open Comparison of Subjective Well-being in Schizophrenic Out-patients Treated with Quetiapine XR (SEROQUEL XR™) or Oral Risperidone at Flexible Dose in a Naturalistic Setting
Medical condition
Schizophrenic Disorders
Phase
Phase 3
Healthy volunteers
No
Study drug
Quetiapine XR, Risperidone
Sex
All
Actual Enrollment
798
Study type
Interventional
Age
18 Years - 65 Years
Date
Study Start Date: 01 Jan 2008
Primary Completion Date: 01 Oct 2009
Study Completion Date: 01 Oct 2009
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Oct 2012 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: Quetiapine XR | Drug: Quetiapine XR Oral, once daily, tablets of 400 mg to 800 mg Other Name: Seroquel XR |
| Active Comparator: Risperidone | Drug: Risperidone Oral, once daily, tablets of 2 mg to 6 mg Other Name: Risperdal |
Contacts
Investigators
Principal Investigator
Martin Brecher
AstraZeneca
